Literature DB >> 19573562

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

Talib Abbas1, Emilie Faivre, Christian Hölscher.   

Abstract

Type 2 diabetes has been identified as a risk factor for Alzheimer disease (AD). Insulin signalling is often impaired in AD, contributing to the neurodegeneration seen in AD. Previous studies have shown that the incretin glucagon-like peptide 1 (GLP-1) helps to normalise insulin signalling in type 2 diabetes. GLP-1 also plays important roles in neuronal activity and brain functions. We tested the specific role of GLP-1 receptors in synaptic plasticity and cognitive processes in a GLP-1 receptor knockout (Glp1r(-/-)) mouse model. In an open field assessment, no general difference in exploratory and anxiety was found except for a small decrease in running speed was found (p<0.05). In an object recognition task, Glp1r(-/-) mice explored objects in a similar way to WT controls but did not learn to differentiate between novel and familiar objects (p<0.05) while in an object relocation task, no impairment was observed. In a water maze task, Glp1r(-/-) mice were impaired in the acquisition phase (p<0.001), and also in the probe recall task (p<0.05). LTP in area CA1 of the hippocampus was severely impaired in Glp1r(-/-) mice (p<0.0001). Paired-pulse facilitation was also impaired at 25ms interstimulus interval (p<0.05) but not at longer intervals. The results demonstrate that the murine GLP-1R plays an important role in the control of synaptic plasticity and in some forms of memory formation. The results shed light on the molecular processes that underlie the neuroprotective properties of GLP-1 analogues in animal models of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573562     DOI: 10.1016/j.bbr.2009.06.035

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  71 in total

1.  Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits.

Authors:  Peter J Fried; Lukas Schilberg; Anna-Katharine Brem; Sadhvi Saxena; Bonnie Wong; Aaron M Cypess; Edward S Horton; Alvaro Pascual-Leone
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 2.  Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer's Disease.

Authors:  Stephen M Day; Tao Ma
Journal:  Neurosci Bull       Date:  2019-03-07       Impact factor: 5.203

3.  Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

Authors:  Liqin Qi; Zhou Chen; Yanping Wang; Xiaoying Liu; Xiaohong Liu; Linfang Ke; Zhongjie Zheng; Xiaowei Lin; Yu Zhou; Lijuan Wu; Libin Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 4.  Energy intake and exercise as determinants of brain health and vulnerability to injury and disease.

Authors:  Mark P Mattson
Journal:  Cell Metab       Date:  2012-11-15       Impact factor: 27.287

5.  Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease.

Authors:  Yongfu Wang; Long Wu; Jianping Li; Du Fang; Changjia Zhong; John Xi Chen; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.

Authors:  Jayasankar Kosaraju; R M Damian Holsinger; Lixia Guo; Kin Yip Tam
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

Review 7.  Running forward: new frontiers in endurance exercise biology.

Authors:  Glenn C Rowe; Adeel Safdar; Zolt Arany
Journal:  Circulation       Date:  2014-02-18       Impact factor: 29.690

8.  The impact of dietary energy intake on cognitive aging.

Authors:  Mark P Mattson
Journal:  Front Aging Neurosci       Date:  2010-03-08       Impact factor: 5.750

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 10.  Alzheimer's disease and insulin resistance: translating basic science into clinical applications.

Authors:  Fernanda G De Felice
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.